Could SIRPA expression predict response to anti-PD-1 immunotherapy?

Kristen Jogerst; Genevieve Boland

doi:10.1016/j.ccell.2022.10.003

Could SIRPA expression predict response to anti-PD-1 immunotherapy?

Cancer Cell. 2022 Nov 14;40(11):1269-1270. doi: 10.1016/j.ccell.2022.10.003. Epub 2022 Nov 3.

Authors

Kristen Jogerst¹, Genevieve Boland²

Affiliations

¹ Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
² Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: gmboland@mgh.harvard.edu.

PMID: 36332626
DOI: 10.1016/j.ccell.2022.10.003

Abstract

Immune checkpoint inhibitors (ICIs) offer significant promise for patients with melanoma; however, many patients succumb to de novo or acquired ICI resistance. In this issue of Cancer Cell, Zhou et al. propose a mechanism for signal-regulatory protein α1 (SIRPα) expression and describe how its loss may contribute to immunotherapy resistance.

Publication types

Comment

MeSH terms

Antigens, Differentiation
Humans
Immunologic Factors
Immunotherapy*
Melanoma* / drug therapy
Melanoma* / genetics
Receptors, Immunologic

Substances

Immunologic Factors
SIRPA protein, human
Antigens, Differentiation
Receptors, Immunologic